QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)

MaxCyte (MXCT) Stock Forecast, Price & News

$3.17
+0.09 (+2.92%)
(As of 09/28/2023 ET)
Compare
Today's Range
$3.01
$3.22
50-Day Range
$3.02
$4.94
52-Week Range
$2.99
$7.50
Volume
904,165 shs
Average Volume
494,848 shs
Market Capitalization
$328.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

MaxCyte MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
231.2% Upside
$10.50 Price Target
Short Interest
Bearish
2.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$120,981 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.37) to ($0.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

592nd out of 969 stocks

Commercial Physical Research Industry

10th out of 14 stocks


MXCT stock logo

About MaxCyte (NASDAQ:MXCT) Stock

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

MXCT Price History

MXCT Stock News Headlines

Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
PRTS, CRBU and NDLS are among after hour movers
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Recap: MaxCyte Q1 Earnings
MaxCyte Is Poised For A Strong Rebound
MaxCyte, Curamys In Strategic Platform License Deal
MaxCyte, Inc. (NASDAQ: MXCT)
See More Headlines
Receive MXCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

MXCT Company Calendar

Last Earnings
8/09/2023
Today
9/28/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MXCT
Employees
125
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.50
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+231.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-23,570,000.00
Pretax Margin
-80.22%

Debt

Sales & Book Value

Annual Sales
$44.26 million
Book Value
$2.47 per share

Miscellaneous

Free Float
97,325,000
Market Cap
$328.22 million
Optionable
Optionable
Beta
0.80
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Douglas Arthur Doerfler (Age 67)
    Founder, Pres, CEO & Exec. Director
    Comp: $1.2M
  • Dr. Cenk Sumen Ph.D. (Age 49)
    Chief Scientific Officer
    Comp: $575.6k
  • Mr. Maher Masoud (Age 48)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $612.07k
  • Mr. Douglas J. Swirsky CFA (Age 54)
    CPA, Chief Financial Officer
  • Mr. Ronald Evan Holtz CPA (Age 65)
    Ph.D., Exec. VP of Admin.
  • Mr. Sean Menarguez
    Director of Investor Relations
  • Mr. Thomas Michael Ross (Age 62)
    Exec. VP of Global Sales & Marketing
  • Dr. J. Stark Thompson Ph.D. (Age 81)
    Consultant
  • Dr. James Brady Ph.D.
    Sr. VP of Technical Applications & Customer Support
  • Dr. Sarah Haecker Meeks Ph.D.
    Sr. VP of Bus. Devel.













MXCT Stock - Frequently Asked Questions

Should I buy or sell MaxCyte stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MaxCyte in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MXCT shares.
View MXCT analyst ratings
or view top-rated stocks.

What is MaxCyte's stock price forecast for 2023?

1 Wall Street research analysts have issued 1-year target prices for MaxCyte's shares. Their MXCT share price forecasts range from $9.00 to $12.00. On average, they predict the company's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 231.2% from the stock's current price.
View analysts price targets for MXCT
or view top-rated stocks among Wall Street analysts.

How have MXCT shares performed in 2023?

MaxCyte's stock was trading at $5.46 at the beginning of the year. Since then, MXCT shares have decreased by 41.9% and is now trading at $3.17.
View the best growth stocks for 2023 here
.

When is MaxCyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our MXCT earnings forecast
.

How were MaxCyte's earnings last quarter?

MaxCyte, Inc. (NASDAQ:MXCT) released its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.10) EPS for the quarter, meeting analysts' consensus estimates of ($0.10). The company had revenue of $9.04 million for the quarter, compared to analysts' expectations of $11 million. MaxCyte had a negative trailing twelve-month return on equity of 13.09% and a negative net margin of 80.22%.

When did MaxCyte IPO?

(MXCT) raised $150 million in an initial public offering on Friday, July 30th 2021. The company issued 12,000,000 shares at $11.50-$13.50 per share.

What is MaxCyte's stock symbol?

MaxCyte trades on the NASDAQ under the ticker symbol "MXCT."

Who are MaxCyte's major shareholders?

MaxCyte's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.71%), Casdin Capital LLC (4.56%), Stonepine Capital Management LLC (3.83%), ArrowMark Colorado Holdings LLC (2.49%), Granahan Investment Management LLC (1.83%) and Blue Water Life Science Advisors LP (1.82%). Insiders that own company stock include Casdin Partners Master Fund, L, Douglas Doerfler, John Joseph Johnston, Richard Douglas and Thomas M Ross.
View institutional ownership trends
.

How do I buy shares of MaxCyte?

Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MaxCyte's stock price today?

One share of MXCT stock can currently be purchased for approximately $3.17.

How much money does MaxCyte make?

MaxCyte (NASDAQ:MXCT) has a market capitalization of $328.22 million and generates $44.26 million in revenue each year. The company earns $-23,570,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis.

How many employees does MaxCyte have?

The company employs 125 workers across the globe.

How can I contact MaxCyte?

MaxCyte's mailing address is 22 FIRSTFIELD ROAD SUITE 110, GAITHERSBURG MD, 20878. The official website for the company is maxcyte.com. The company can be reached via phone at 301-944-1700, via email at ir@maxcyte.com, or via fax at 301-944-1703.

This page (NASDAQ:MXCT) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -